The botanical longevity formula was reverse-engineered from the molecular target map of a prescription senolytic drug regimen. Two years after launch, the independent lab behind it is making the full development research public for the first time.

VALENCIA, CA (June 14, 2026)— Cellular senescence has become one of the most closely watched frontiers in aging science. As the body ages, worn-out senescent cells, often referred to as “zombie” cells, accumulate instead of clearing out, and a fast-growing body of research is examining what role they play in how tissues age — and whether clearing or quieting them may support healthy aging. The compounds being studied to do this, known as senotherapeutics, fall into two groups: senolytics and senomorphics.

One novel approach to clearing these cells, and the focus of several recent studies, is the D+Q combination, which pairs dasatinib — a prescription leukemia medication, approved in 2006, that works by inhibiting tyrosine kinases — with quercetin, an antioxidant flavonoid, available at most vitamin shops. D+Q has become one of the most active starting points in senolytic research, and early human studies have examined its effect on markers of senescent cells. Research into the combination remains ongoing.

NEUROmergence® takes that research as a blueprint — and runs it in an entirely natural direction. Rather than starting from a trend, MDS Labs® began with the documented molecular targets of dasatinib and worked backward, building the formula compound by compound from the broader published literature: mapping the kinases and signaling pathways dasatinib acts on, then selecting well-researched botanical compounds reported to act on those same targets, at amounts consistent with established human use. A 2020 review of plant-derived protein kinase inhibitors served as an early starting point; and computational target prediction helped fill gaps where direct studies were limited.

The result is a dietary supplement that combines eight botanical compounds: quercetin, fisetin, spermidine, pterostilbene, rutin, berberine, a standardized Sophora flavescens (Ku Shen) extract providing oxymatrine and lupeol — fractionated and standardized in-house — and a standardized senna extract (sennoside B). NEUROmergence® includes 500 mg of quercetin, one of the two compounds in the original D+Q research. Each ingredient was chosen for a well-documented safety profile and on the basis of published research examining its activity on senolytic- and senomorphic-related pathways, including BCR-Abl, the SRC family (SRC, FYN, LYN), BCL-2, c-KIT, CSF1R, PDGFR-β, c-Met, and CDK2, alongside research on the activation of AMPK.*

In the two years since its 2024 launch, NEUROmergence® has grown into one of MDS Labs®’ most popular products, earning a loyal, repeat customer base within the longevity community. Customers frequently describe feeling sharper, more focused, and more energized,* and the product’s intermittent, low-frequency dosing has made it easy to sustain as a long-term routine.

Now, MDS Labs® is making the full research behind NEUROmergence® public for the first time. The report — now available to read on the lab’s website — documents the entire development process from start to finish: the molecular target map drawn from dasatinib’s published profile, the rationale and published evidence behind every compound, graded by strength so readers can see exactly how solid each piece is, and a candid accounting of which of dasatinib’s targets the botanical set does and does not cover. It presents the formula as a research-informed design hypothesis rather than a demonstrated therapy, is openly transparent about the limits of the current evidence, and situates the work alongside independent, peer-reviewed research that reached the same question by a different method. For a category often built on bold claims and thin sourcing, publishing the reasoning, the citations, and the gaps is a deliberate choice — one that invites scrutiny rather than avoiding it.

“NEUROmergence® was never built backward from a marketing claim — it was built forward from the target map of a senolytic regimen and the published research on plant compounds that act on those same targets,” said Adam Geller, President and CEO of MDS Labs®. “After two years, releasing the full research — including where the evidence is strong and where it still needs work — felt like the honest next step. We would rather hand people the reasoning and let them judge it for themselves.”

NEUROmergence® follows a simple, intermittent two-day dosing cycle, taken roughly once or twice a month, and is available for purchase directly to consumers at mdslabs.shop, without a prescription.

Read the full research paper here.

About MDS Labs®
MDS Labs® is a research-focused dietary supplement company, part of the Reventek® family of brands, formulating products from carefully sourced, standardized ingredients.

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.